Study	Reason for exclusion
Aledort 1994	Prospective observational study.
Ali 2018	Includes participants with inhibitors.
Andreeva 2015	Unclear if participants were previously treated (conference abstract only).
Antunes 2013	Includes participants with inhibitors.
ASPIRE 2020	Prospective observational study.
Astermark 1999	Retrospective observational study.
Astermark 2019	Intervention includes the anti‐Tissue Factor Pathway Inhibitor (TFPI),concizumab, which is not a clotting factor therapy. This could be eligible for the subsequent review on non‐clotting factor therapies.
Bertolet 2020	Intervention includes emicizumab, which is not a clotting factor therapy.
Booth 2017	Prospective observational study
Brackmann 1992	Retrospective observational study.
Carlsson 1997	Includes children previously on prophylaxis.
Chakraborty 2018	Includes children on primary prophylaxis.
Chowdary 2013	Intervention includes the anti‐Tissue Factor Pathway Inhibitor (TFPI), concizumab, which is not a clotting factor therapy.
Chowdary 2017	Intervention is an investigational RNA interference (RNAi) therapeutic, not a clotting factor therapy.
Chozie 2018	Includes children on primary prophylaxis.
Chuansumrit 1995	Retrospective observational study.
Collins 2010	Prospective observational cross‐over study.
Collins 2014	Includes children on primary prophylaxis.
Courter 2001	Prospective observational study.
Curry 2019	Includes people on primary prophylaxis.
Davydkin 2015	Unclear if participants were children or previously treated (conference abstract only).
Dzinaj 1996	Prospective observational study.
Eichler 2018	Intervention includes concizumab, which is not a clotting factor therapy.
ENJOIH 2010	Includes participants with inhibitors.
Escuriola 2019	Pharmacokinetics evaluated.
ESPRIT 2011	Pediatric population on primary prophylaxis.
Feldman 2006	Prospective observational single‐arm dose‐escalation study.
Fernandez‐Bello 2017	Pharmacokinetics evaluated in participants with inhibitors.
Fischer 2005	Retrospective observational study.
HAVEN 1 2017	Includes participants with inhibitors.
Hazendonk 2015	Pharmacokinetic parameters evaluated.
INHIBIT 2014	Children on primary prophylaxis.
Kavakli 1997	Prospective observational study.
Khayat 2016	Children on primary prophylaxis.
Kids B‐LONG 2017	Prospective observational study in children.
Konkle 2016	Retrospective observational study.
Kreuz 1998	Prospective observational study.
LEOPOLD I 2015	Participants on primary prophylaxis
Liesner 1996	Retrospective observational study.
Lofqvist 1997	Retrospective observational study.
Ma 2015	Retrospective observational study.
Manco‐Johnson 1994	Prospective observational study.
Manco‐Johnson 2007	Children on primary prophylaxis.
NCT03315455	Intervention includes emicizumab, which is not a clotting factor therapy.
NCT04303559	Intervention includes emicizumab, which is not a clotting factor therapy.
Nemes 2007	Prospective observational single‐arm study.
Nilsson 1970	Retrospective observational study with historical control.
Nilsson 1976	Prospective observational study with historical control.
Nilsson 1992	Retrospective observational study.
PERSEPT 1 2017	Includes participants with inhibitors.
Petrini 1991	Retrospective observational study.
Pettersson 1981	Retrospective observational study with historical control.
PRO‐FEIBA 2010	Includes participants with inhibitors.
PROTECT VIII 2017	Includes participants on primary prophylaxis.
Ragni 2017	Pilot feasibility study with cross‐over design.
Ramsay 1973	Prospective observational study.
Royal 2002	Retrospective observational study with parallel groups.
Santagostino 2016	Prospective observational single‐arm study.
Schimpf 1977	Prospective observational cross‐over study.
Schobess 2008	Prospective observational study.
Shah 2019	Pharmacokinetic parameters evaluated.
Shapiro 2018	Intervention includes concizumab, which is not a clotting factor therapy.
Smith 1996	Retrospective observational switch study.
Smith 2018	Includes children on primary prophylaxis
Solms 2020	Pharmacokinetic parameters evaluated.
Song 2012	Ad‐hoc analysis of a randomized controlled trial. Protocol or full study with results not found on trial registries. Also, the comparison focused on the degree of availability of factor concentrates per country i.e. low versus high IU/capita countries.
Szucs 1996	Prospective observational study.
Tagliaferri 2008	Retrospective observational switch study.
Van den Berg 2001	Retrospective observational single‐arm study.
Verma 2016	Includes children on primary prophylaxis
Windyga 2014	No randomization in the comparison arm assessing outcome of interest (hemostatic efficacy).
Wu 2011	Prospective observation with historical control.
Young 2015	Prospective observational study in children.
Young 2017	Prospective dose and dose‐interval comparison study (conference abstract only).